Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
FATE Surges More Than 152% in Three Months: Here's Why?
by Zacks Equity Research
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies
by Zacks Equity Research
Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.
3 Large Drugmakers Set to Rule the Sector in 2021
by Kinjel Shah
Large Cap Pharmaceuticals industry players maintain a cautious outlook after mixed Q3 show. COVID-19 vaccine development efforts play a crucial role in driving the industry. PFE, MRK, NVS may prove to be good additions to your portfolio.
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.
Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug
by Zacks Equity Research
Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
by Zacks Equity Research
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
Novartis (NVS) to Acquire Neuroscience Company for Up to $770M
by Zacks Equity Research
Novartis (NVS) to buy neuroscience company, Cadent, for up to $770 million.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use
by Zacks Equity Research
Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.
Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.
Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.
Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment
by Zacks Equity Research
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
Should Value Investors Consider Novartis (NVS) Stock Now?
by Zacks Equity Research
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
by Zacks Equity Research
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.